Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
…, BP Nutley, FI Raynaud, P Sheldrake, M Walton…
Index: Wilson, Stuart C.; Atrash, Butrus; Barlow, Clare; Eccles, Susan; Fischer, Peter M.; Hayes, Angela; Kelland, Lloyd; Jackson, Wayne; Jarman, Michael; Mirza, Amin; Moreno, Javier; Nutley, Bernard P.; Raynaud, Florence I.; Sheldrake, Peter; Walton, Mike; Westwood, Robert; Whittaker, Steven; Workman, Paul; McDonald, Edward Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 22 p. 6949 - 6965
Full Text: HTML
Citation Number: 19
Abstract
The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound αSβR- 21 inhibits CDK2/cyclin E with IC50= 30nM, CDK7-cyclin H with IC50= 1.3 μM, and CDK9- ...
Related Articles:
[Oumata, Nassima; Ferandin, Yoan; Meijer, Laurent; Galons, Herve Organic Process Research and Development, 2009 , vol. 13, # 3 p. 641 - 644]
[Journal of Medicinal Chemistry, , vol. 40, # 4 p. 408 - 412]
[Bioorganic and Medicinal Chemistry, , vol. 19, # 22 p. 6949 - 6965]
[Bioorganic and Medicinal Chemistry, , vol. 19, # 22 p. 6949 - 6965]
[Bioorganic and Medicinal Chemistry, , vol. 19, # 22 p. 6949 - 6965]